Overactive Bladder - Results from #1460

Brain-bladder control network: The unsolved 21st century urological mystery - Abstract March 19, 2015

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: The results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials - Abstract March 18, 2015

Pathogens in urine from a female patient with overactive bladder syndrome detected by culture-independent high throughput sequencing: A case report - Abstract March 17, 2015

Chiropractic management of pubic symphysis shear dysfunction in a patient with overactive bladder - Abstract March 16, 2015

A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment - Abstract March 13, 2015

Use of local estrogenotherapy in urology and pelviperineology: A systematic review - Abstract March 13, 2015

Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients - Abstract March 11, 2015

SUFU WM 2015 - Single center experience: Sacral neuromodulation reprogramming rates - Session Highlights March 11, 2015

Comparison of biofeedback therapy in children with treatment-refractory dysfunctional voiding and overactive bladder - Abstract March 11, 2015

Idiopathic overactive bladder and BOTOX®: Literature review - Abstract March 10, 2015

SUFU WM 2015 - Efficacy profile in OAB patients less than 65 and ≥ 65 years of age - Session Highlights March 9, 2015

SUFU WM 2015 - Trends in second line therapy use for OAB before and after approval FDA approval of onabotulinum toxin A (BTA) - Session Highlights March 9, 2015

SUFU WM 2015 - Predictors of incomplete bladder emptying requiring CIC following intradetrusor onabotulinum toxin A (BTA) - Session Highlights March 9, 2015

SUFU WM 2015 - Onabotulinum toxin A (BTA) in patients with a history of prior radiation therapy - Session Highlights March 9, 2015

SUFU WM 2015 - The efficacy of onabotulinum toxin A (BTA- BOTOX®) in patients with urgency urinary incontinence who have failed sacral neuromodulation (InterStim®) - Session Highlights March 9, 2015

SUFU WM 2015 - Consistent long-term efficacy and safety of repeat BTA injections in patients with neurogenic detrusor overactivity (NDO): Final results of up to four years treatment - Session Highlights March 9, 2015

SUFU WM 2015 - Factors impacting patient tolerability and procedure time for intravesical onabotulinumtoxin A injection - Session Highlights March 9, 2015

Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: Videourodynamic evaluation - Abstract March 6, 2015

The role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO) - Abstract March 4, 2015

SUFU WM 2015 - Neuromodulation/OAB podium - Session Highlights March 2, 2015

Page 74 of 122